<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="799697" id="root" date="1997-08-14" xml:lang="en">
<title>USA: TABLE - NeoTherapeutics Inc Q2 results.</title>
<headline>TABLE - NeoTherapeutics Inc Q2 results.</headline>
<dateline>IRVINE, Calif. 1997-08-14</dateline>
<text>
<p>NEOTHERAPEUTICS INC. AND SUBSIDIARIES</p>
<p>			 (A Development Stage Enterprise)</p>
<p>			 Summary Statement of Operations</p>
<p>				(Unaudited)</p>
<p>			     Three Months	     Six Months</p>
<p>				 Ended			 Ended</p>
<p>				 June 30,		  June 30,</p>
<p>				1997	1996	 1997	 1996</p>
<p> Revenues	   $	 -- $	 -- $	 -- $	 --</p>
<p>Operating Expenses:</p>
<p>Research and</p>
<p>  development	  836,206     48,567  1,385,021     82,637</p>
<p>General and</p>
<p>administration expense</p>
<p>			   569,357    134,877  1,068,321    160,423</p>
<p>Total operating</p>
<p>    expenses	 1,405,563    183,444  2,453,342    243,060</p>
<p>Loss from operations</p>
<p>			 1,405,563    183,444  2,453,342    243,060</p>
<p>Other income (expense),</p>
<p>net, principally</p>
<p>   interest	    193,978   (13,842)    422,782   (27,639)</p>
<p> Net loss	    1,211,585    197,286  2,030,560    270,699</p>
<p> Net loss per share   (0.23)     (0.07)     (0.38)     (0.11)</p>
<p>Weighted average</p>
<p>shares outstanding</p>
<p>			 5,364,884  2,767,060  5,363,354  2,521,308</p>
<p>				   Summary Balance Sheets</p>
<p>							Jun 30,    Dec. 31,</p>
<p>							  1997	  1996</p>
<p>						 (Unaudited)</p>
<p> Cash and cash equivalents		$ 3,297,648 $ 9,995,062</p>
<p>Marketable securities and other</p>
<p>  investments				   8,110,157   5,702,114</p>
<p> Other receivables and deposits	     338,829     403,159</p>
<p> Total current assets			11,746,634  16,100,335</p>
<p> Property and equipment, net		2,727,845     132,509</p>
<p> Marketable securities and other	  1,972,857   1,746,432</p>
<p> Total assets				  16,447,336  17,979,276</p>
<p> Current liabilities			  1,785,018   1,357,196</p>
<p> Stockholders equity			 14,662,318  16,622,080</p>
<p>Total liabilities and stockholders equity</p>
<p>						   16,447,336  17,979,276</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-14"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C15">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-14"/>
  </code>
  <code code="C151">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-14"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-14"/>
  </code>
</codes>
<dc element="dc.date.created" value="1997-08-14"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-08-14"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="IRVINE, Calif."/>
<dc element="dc.creator.location.country.name" value="USA"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
